Signal Report · US
BMY BUY
Composite decision report grounded in 1-XH strategy signals and multi-agent debate, generated by DeepSeek at 2026-06-30 08:48.
🎯 Final Decision
Action
BUY
Weight
60%
Confidence
65%
Variant
xiaohan_gogo_v2
Reasons
- Multi-timeframe bottom cluster is a rare, historically reliable mean-reversion setup.
- Top 3% factor rank (+0.87 z) despite model exclusion suggests strong quant support.
- Oversold bollinger and elevated downside vol favor a snap-back rally.
- Bear counters are weak: negative sharpe/beta at bottoms is normal, no catalyst is irrelevant for quant patterns.
- Confidence tempered by probabilistic signal (0.80) and lack of fundamental catalyst.
Bull Case (Analyst)
- The technical signal is strongly bullish: the 1-XH family triggered a "buy" with a score of 0.80, and the gogo_detail shows simultaneous bottoms across the 1h, 2h, 3h, and 4h timeframes plus a daily bottom — a rare multi-timeframe exhaustion setup that historically precedes mean-reversion rallies. - The cross-sectional factor view ranks BMY 7th out of 251 stocks (top 2.8%), with a composite z-score of +0.87, indicating strong factor alignment for longs in the current BULL regime catalog. - The top lifters are powerful: xh_gogo_score (+2.94 z) directly corroborates the technical signal, while bollinger_b_20d (+1.59) suggests the stock is oversold on a 20-day basis, and downside_vol_60d (+0.76) indicates elevated volatility that often snaps higher in a reversal. - The stock closed at $58.55, above both the ema_low_fast ($56.72) and ema_high_slow ($56.40), confirming the technical uptrend initiation from the multi-timeframe bottom cluster.
Bear Case (Analyst)
- The cross-sectional factor view explicitly notes BMY is "not in the production basket" — the model did not select it for the top decile this period, suggesting the composite z-score of +0.87, while strong, was insufficient to warrant inclusion in the actual trading portfolio. - The top draggers are concerning: sharpe_60d (-0.67 z) and beta_60d (-0.64 z) indicate poor risk-adjusted returns and defensive/low-beta characteristics that may limit upside in a BULL regime that favors higher-beta names. - The sole news item is about AbbVie's acquisition of Apogee, not BMY — there is no company-specific catalyst or positive sentiment to support the technical signal, leaving the bull case entirely dependent on mean-reversion patterns. - Momentum_6m is a dragger (-0.04 z), suggesting the stock has been weak over a longer horizon, and a multi-timeframe bottom cluster does not guarantee a sustained trend reversal in the absence of fundamental or sector tailwinds.
Devil's Advocate
COUNTER TO BULL: - The 1-XH family "buy" score of 0.80 is not 1.0 — it's a probabilistic signal, not a guarantee. Multi-timeframe bottoms can also form in descending triangles that break lower; the "rare" setup may simply reflect a slow bleed that hasn't finished. - Rank 7th out of 251 with a +0.87 z-score is good, but the model explicitly excluded BMY from the production basket. This implies the composite score is below a materiality threshold — the quant process is saying "look, but don't touch." - Bollinger_b_20d at +1.59 z means oversold, but oversold can stay oversold. Downside_vol_60d at +0.76 z cuts both ways: elevated vol snaps higher in reversals, but also snaps higher in breakdowns. - Closing above ema_low_fast and ema_high_slow is a lagging confirmation — these moving averages are already sloping down if the stock just bounced from a bottom. The "uptrend initiation" is one bar old. COUNTER TO BEAR: - "Not in the production basket" is a model-specific rule, not a fundamental rejection. The composite z-score of +0.87 is still in the top 3% of the universe — the production basket may have a higher threshold due to risk constraints, not signal quality. - Sharpe_60d and beta_60d being negative is exactly what you'd expect at a multi-timeframe bottom: the stock has been punished, risk-adjusted returns are trash, and beta collapsed. That's the entry point, not the reason to avoid. - No company-specific catalyst is a weak bear argument — mean-reversion patterns in quant models are explicitly designed to capture non-fundamental dislocations. The absence of news is not evidence against the pattern. - Momentum_6m being a slight dragger (-0.04 z) is noise-level. A stock can have weak 6-month momentum and still rally 10% in a week on a technical flush — the bear case is conflating horizon.
Technical Signal (1-XH)
action
buy
score
0.80
variant
xiaohan_gogo_v2
timestamp
2026-06-29 15:30:00
close
58.55
ema_low_fast
56.72
ema_high_slow
56.4
gogo_score
0.8
gogo_detail
1h_bottom,2h_bottom,3h_bottom,4h_bottom,1h_blue_upper_above_yellow_upper,daily_bottom
📈 Backtest Track Record xiaohan_gogo_v2 · signals simulated over available history (~3-month 30-min window, accumulating daily)
Trades
1
Win rate
100%
Avg / trade
+5.4%
Total (compounded)
+5%
best / worst
+5.4% / +5.4%
avg holding
6.2 days
open position
yes — marked-to-market +5.4%
| Entry | Exit | Entry | Exit | Return | Exit reason |
|---|---|---|---|---|---|
| 2026-06-23 | open | 55.52 | 58.55 | +5.4% | open_position_mark_to_market |
News & social (1 items)
-
wsj.comAbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion - WSJThis copy is for your personal, non-commercial use only. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/business/deals/abbvie-to-buy-apo…